Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 6.07% | -3.97% | |||
| Gross Profit | -6.07% | 3.97% | |||
| SG&A Expenses | -15.08% | 11.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.01% | -0.05% | |||
| Operating Income | 0.01% | 0.05% | |||
| Income Before Tax | 0.00% | -1.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.08% | -1.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.08% | -1.30% | |||
| EBIT | 0.01% | 0.05% | |||
| EBITDA | -0.01% | -0.01% | |||
| EPS Basic | 6.06% | 0.46% | |||
| Normalized Basic EPS | 6.26% | -0.74% | |||
| EPS Diluted | 6.06% | 0.46% | |||
| Normalized Diluted EPS | 6.26% | -0.74% | |||
| Average Basic Shares Outstanding | 6.37% | 1.76% | |||
| Average Diluted Shares Outstanding | 6.37% | 1.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||